Companies and Markets
Call us on +44 (0) 203 086 8600
Market Research A to Z | Company Profiles A to Z | RegisterRegister | Contact UsContact Us | Shopping Basket Shopping Basket
+44 (0) 203 086 8600 Call us on

DNA Vaccines: Technologies and Global Markets

4259

Select License Type

Electronic License

Electronic License

An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.

£4,259.00

Change Currency

GBP EURO USD
GBP EURO USD

Market

Healthcare and Medical

Report Type

Market Research

Country

Global

Published

1 September 2009

Number of Pages

213

Report Delivery

Email

Delivery Lead Time

1-3 hours, 24 hour max

Publisher

BCC Research

File Format

PDF

25% off BCC reports which are more than 2 years old during December 25% off BCC reports which are more than 2 years old during December

Discounted price shows in basket.

- Overall sales in the DNA vaccines market were worth $141 million in 2008, and increased to an estimated $193 million in 2009. By 2014, it is projected to increase substantially to $2.7 billion, for a 5-year compound annual growth rate (CAGR) of 69.5%.

- The human health vaccine segment was valued at $12 million in 2008. This is expected to increase to nearly $24 million in 2009, and is projected to reach almost $2.3 billion in 2014, for a 5-year CAGR of 149.6%.

- Sales in the research tools segment amounted to $73 million in 2008, increased to nearly $92 million in 2009, and are projected to reach nearly $166 million in 2014, for a 5-year CAGR of 12.6%.


The vaccine industry is rapidly changing from a mostly empirical approach to a rational design approach. Rapid developments in molecular biology, DNA synthesis, and immunobiology enable rational design approaches. These technologies allow highly targeted vaccines aimed at specific epitopes. The result is new vaccines for a wider range of diseases than was previously feasible, including a new class of therapeutic vaccines. These new technologies allow pharmaceutical firms to discover and develop high-value vaccines for novel applications, creating a substantial new market opportunity.

DNA vaccines have many potential advantages, including specific targeting, use of multiple genes to enhance immunity, and reduced risk compared with conventional vaccines. Translating the advantages of DNA vaccines into the clinic has historically been difficult; however, new advances in the fields of vaccine design and DNA delivery are addressing the previous issues. Achievements in these fields promise to overcome the translational hurdles and create strategic opportunity. This report analyzes these trends and their effects on the future markets for DNA vaccines.

The technological and structural changes occurring in the vaccine industry are strong driving forces for revitalizing this particular market and providing new growth opportunities. It is important that biotechnology and pharmaceutical firms understand the technology and market dynamics within this industry in order to best develop strategic plans and actions.

Based on these market and technology dynamics, it is especially timely to examine the future DNA vaccines markets.

INTENDED AUDIENCE

We have compiled a study of DNA vaccine technologies that will be commercially important in the major market segments, including cancer, infectious diseases, animal health, allergies, and biodefence.

We present DNA vaccine delivery and synthesis technologies; growth driving forces; product formats; market applications; clinical trials; industry structure and alliances; and global sales forecasts for the period 2009 through 2014. We estimate the future use of DNA vaccines in the important disease markets, and by technology.

This report will serve as a useful industry guide for biotechnology, DNA plasmid, gene therapy, DNA delivery, pharmaceutical, vaccine, animal health, and biodefence companies; as well as for suppliers of genetic tools, synthetic genes, and vaccine adjuvants. It will also be of interest to professionals within the regulatory agencies to understand the scope and pace of DNA vaccine technologies as they move from clinical trials into the market.

SCOPE OF REPORT

The study scope includes DNA vaccine products that are commercial or likely to be commercialized within the next 5 years. Both human and animal health markets are studied. DNA vaccine delivery technologies are also included. DNA vaccine candidates in clinical trials are examined by indication, and future market growth from 2009 through 2014 is estimated.

The role that DNA vaccines play in the overall vaccines industry is examined, as well as how the vaccine industry structure and dynamics are changing.

We examine DNA synthesis, biotechnology, and pharmaceuticals firms; strategic industry alliances; and the role of gene delivery and synthesis technologies. The major markets for DNA vaccines, including infectious diseases, cancers, animal health, allergies, and biodefense, are analyzed and the main companies in these fields are highlighted.

 

Speak to an Advisor

Call us on
+44 (0) 203 086 8600

Select License Type

Electronic License

Electronic License

An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.

£4,259.00

Change Currency

GBP EURO USD

Change Currency

GBP
USD

Visitor Comments

All posts are pre-moderated and must obey the house rules.

Change Currency

GBP
USD

Use our research skills: Get free support

Free Research Support: Let us do the work for you and find information from public and private sources of information. Contact us now and we can save you time and money.......Free Research Support

December Discounted Prices: Contact us to ask about our special discounts available in December

For the last month in 2014 we are offering discounted prices on a selection of new reports. Please contact us on 00 44 (0) 203 0868600 or via email (click here to email) to ask about prices and special discounts.

Available during December and the run-up to Christmas; Discounted prices on a selection of our reports.

Find all the research at the best prices. Great promotions being offered during December!

We are offering our clients substantial savings on the best research available during December. Please contact us either via emailor by calling our team to discuss your specific research needs on Tel: 00 44 (0) 203 0868600. We look forward to being able to find you the research you require at good prices.

Accessibility
Close

Contrast settings

Text size settings